Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-07-19
2011-07-19
Johannsen, Diana (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023100, C536S023500, C536S024310, C536S024330, C536S025320
Reexamination Certificate
active
07981603
ABSTRACT:
The present invention provides methods and kits for identifying an increased risk of developing cancer in a subject. The methods include analyzing a first biological sample, such as a blood sample, from the subject for loss of imprinting of the IGF2 gene. According to the methods a loss of imprinting is indicative of an increased risk of developing cancer. The method can include analyzing genomic DNA from the sample for altered methylation of the IGF2 or the H19 gene. The altered methylation for example includes hypomethylation of a differentially methylated region of IGF2, corresponding to SEQ ID NO:1 and/or a polymorphism or fragment thereof, or hypomethylation of a differentially methylated region of H19 corresponding to SEQ ID NO:6, or a polymorphism, or fragment thereof. In certain aspects, hypomethylation of the H19 DMR or the IGF2 DMR indicates an increased risk of developing colorectal cancer.
REFERENCES:
patent: 5552277 (1996-09-01), Nelson et al.
patent: 5786146 (1998-07-01), Herman et al.
patent: 6235474 (2001-05-01), Feinberg
Ahomadegbe, J.C. et al. Loss of imprinting of H19 and IGF2 genes associated with hypomethylation in invasive breast cancers. Proceedings of the American Association for Cancer Research 37:598 (Mar. 1996).
Moore, T.F. GenBank Accession No. Y13633 (Dec. 1997).
Ishihara, K. et al. GenBank Accession No. AF087017 (Oct. 1998).
Ito, Yet al. Human Molecular Genetics 17(17):2633-2643 (Jun. 2008).
Jirtle, R.L. Gastroenterology 126(4):1190-1193 (Apr. 2004).
Jinno, Y. et al. Human Molecular Genetics 5(8):1155-1161 (1996).
Cui, et al., “Loss of Imprinting in Normal Tissue of Colorectal Cancer Patients with Microsatellite Instabililty”,Nature Medicine, 4(11):1276-1280 (Nov. 1998).
Cui, et al., “Loss of Imprinting in Colorectal Cancer Linked to Hypomethylation of H19 and IGF2,”Cancer Research, 62(22):6442-6446 (Nov. 2002).
Nakagawa, et al., “Loss of Imprinting of the Insulin-Like Growth Factor II Gene Occurs by Biallelic Methylation in a Core Region of H19 Associated CTCF-Binding Sites in Colorectal Cancer”,Proceedings of the National Academy Sciences USA, 98(2):591-596 (Jan. 2001).
Bell, A. C. and Felsenfeld, G., “Methylation of a CTCF—dependent Boundary Controls Imprinted Expression of the Igf2 Gene,”Nature, vol. 405, pp. 482-485, 2000.
Douc-Rasy, S. et al., “High Incidence of Loss of Heterozygosity and Abnormal Imprinting of H19 and IGF2 Genes in Invasive Cervical Carcinomas. Uncoupling of H19 and IGF2 Expression and Biallelic Hypomethylation of H19,”Oncogene, vol. 12, pp. 423-430, 1996.
Kaffer, C. R. et al., “A Transcriptional Insulator at the Imprinted H19/Igf2 Locus,”Genes and Development, vol. 14, pp. 1908-1919, 2000.
Reinhart, B. et al., “Shared Role for Differentially Methylated Domains of Imprinted Genes,”Molecular and Cellular Biol., vol. 22, No. 7, pp. 2089-2098, 2002.
Ravenel, J.D., et al.,J. Natl. Cancer Inst. vol. 93, 2001, pp. 1698-1703.
Rainer et al.,Nature, vol. 362, 1993, pp. 747-749.
Feinberg, A.P. and Vogelstein, B., “Hypomethylation Distinguishes Genes of Some Human Cancers From Their Normal Counterparts,”Nature(Lond.), vol. 301, 1983, pp. 89-92.
Feinberg, A.P., et al. “Reduced Genomic 5-Methylcytosine Content in Human Colonic Neoplasia,”Cancer Res., vol. 48, 1988, pp. 1159-1161.
Ogawa, O., et al., “Relaxation of Insulin-Like Growth Factor II Gene Imprinting Implicated in Wilm's Tumour,”Nature(Lond.), vol. 362, 1993, pp. 749-751.
Steelman, M. J., et al., Loss of Imprinting of IGF2 is Linked to Reduced Expression and Abnormal Methylation of H19 in Wilms' Tumour,Nat. Genet, vol. 7, 1994, pp. 433-439.
Uegima, H., et al., “Hot-Stop PCR: a Simple and General Assay for Linear Quantitation of Allele Ratios,”Nat. Genet., vol. 25, 2000, pp. 375-376.
Sullivan, M.J., et al., “Relaxation of IGF2 Imprinting in Wilms Tumours Associated with Specific Changes in IGF2 Methylation,”Oncogene, vol. 18, 1999, pp. 7527-7534.
Moore, T, et al., Multiple Imprinted Sense and Antisense Transcripts, Differential Methylation and Tandem Repeats in a Putative Imprinting Control Region Upstream of MouseIGF2,Proc. Natl. Acad. Sci. USA, vol. 94, Nov., 1997, pp. 12509-12514.
Issa, Jean-Pierre J., et al., “Switch from Monoallelic to Biallelic HumanIGF2Promoter Methylation During Aging and Carcinogenesis.”Proc. Natl. Acad. Sci. USA, vol. 93, Oct. 1996, pp. 11757-11762.
Nakagawa, H., et al., “Loss of Imprinting of the Insulin-Like Growth Factor II Gene Occurs by Biallelic Methylation in a Core Region ofH19-Associated CTCF-binding Sites in Colorectal Cancer,”Proc. Natl. Acad. Sci. USA, Jan. 16, 2001, vol: 98, No. 2, pp. 591-596.
Lee, M.P., et al., “Loss of Imprinting of a Paternally Expressed Transcript, with Antisense Orientation to KvLQT1, Occurs Frequently in Beckwith-Wiedemann Syndrome and is Independent of Insulin-Like Growth Factor II Imprinting,”Proc. Natl. Acad. Sci. USA., vol. 96, Apr. 1999, pp. 5203-5208.
Cui, Hengmi, et al., “Loss of Imprinting ofInsulin-like Growth Factor-IIin Wilms' Tumor Commonly Involves Altered Methylation but not Mutations ofCTCFor Its Binding Site1,”Cancer Research, vol. 61, Jul. 1, 2001, pp. 4947-4950.
Takai, Daiya, et al., “Large Scale Mapping of Methylcytosines in CTCF-binding Sites in the HumanH19Promoter and Aberrant Hypomethylation in Human Bladder Cancer,”Human Molecular Genetics, vol. 10, No. 23, 2001, pp. 2619-2626.
Bartolomei, M.S., et al., “Epigenetic Mechanisms Underlying the Imprinting of the Mouse H19 Gene,”Genes&Dev. 7(9), Sep. 1993, pp. 1663-1673.
Taniguchi, T., et al., “Epigenetic Changes Encompassing theIGF2/H19Locus Associated with Relaxation ofIGF2Imprinting and Silencing ofH19in Wilms Tumor,”Proc. Natl. Acad. Sci., vol. 92, Mar. 1995, pp. 2159-2163.
Catchpoole, D., et al., “Mutation Analysis ofH19andNAP1L4(hNAP2) Candidate Gene andIGF2DMR2 in Beckwith-Wiedemann Syndrome,”J. Med Genet, 37(3) Mar. 2000, pp. 212-215.
Nishihara, S., et al., “Multipoint Imprinting Analysis in Sporadic Colorectal Cancers With and Without Microsatellite Instability,”Int. J. Oncol., 17(2), Aug. 2000, pp. 317-322.
Hofmann, W.K., et al., “Loss of Genomic Imprinting of Insulin-Like Growth Factor 2 is Strongly Associated with Cellular Proliferation in Normal Hematopietic Cells,”Exp. Hematol, 30(4), Apr. 2002, pp. 318-323.
Cui, H., et al., “Loss of Imprinting in Colorectal Cancer Linked to Hypomethylation ofH19andIGF21,” Cancer Research, 62, Nov. 15, 2002, pp. 6442-6446.
Vu, T.H., et al., Symmetric and Asymmetric DNA Methylation in the Human IGF2-H19 Imprinted Region,Genomics, 64(2) Mar. 1, 2000, pp. 132-143.
Schoenherr, C.J., et al., “CTCF Maintains Differential Methylation at theIgf2/H19Locus,”Nat. Genet, 33(1), Jan. 2003, pp. 66-69.
Bell, A.C., et al., “The Protein CTCF is Required for the Enhancer Blocking Activity of Vertebrate Insulators,”Cell, vol. 98, Aug. 6, 1999, pp. 387-396.
Schneider, D. T., et al., “Multipoint Imprinting Analysis Indicates a Common Precursor Cell for Gonadal and Nongonadal Pediatric Germ Cell Tumors1,”Cancer Research, vol. 61, Oct. 1, 2001, pp. 7268-7276.
Uyeno, S., et al., “IGF2But notH19Shows Loss of Imprinting in Human Glioma1,”Cancer Research, vol. 56, Dec. 1, 1996. pp. 5356-5359.
Yun, K., et al., “Analysis ofIGF2Gene Imprinting in Breast and Colorectal Cancer by Allele Specific-PCR,”Journal of Pathology, vol. 187, 1999, pp. 518-522.
DLA Piper (LLP) US
Johannsen Diana
The Johns Hopkins University School of Medicine
LandOfFree
Methods for identifying cancer risk does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying cancer risk, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying cancer risk will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2732211